1. Bing-Neel Syndrome: Update on the Diagnosis and Treatment
- Author
-
Abdelrahman Nanah and Samer Al Hadidi
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,chemistry.chemical_compound ,Humans ,Bruton's tyrosine kinase ,Rare syndrome ,Medicine ,Bing–Neel syndrome ,Immunoglobulin heavy locus ,Brain Diseases ,biology ,business.industry ,Waldenstrom macroglobulinemia ,Syndrome ,Hematology ,medicine.disease ,Pathophysiology ,Molecular analysis ,Oncology ,chemistry ,Ibrutinib ,Mutation ,Myeloid Differentiation Factor 88 ,biology.protein ,Waldenstrom Macroglobulinemia ,business - Abstract
Bing-Neel syndrome (BNS) is a rare syndrome that occurs in patients with Waldenstrom macroglobulinemia and is characterized by lymphoplasmacytic infiltration into the leptomeningeal tissue and/or the central nervous system. It represents an extramedullary manifestation which may translate into various neurological symptoms. Accurate diagnosis of BNS can be established via histologic sampling and cerebrospinal fluid examination with molecular analysis of some genetic markers including immunoglobulin heavy locus rearrangements and MYD88 L265P mutation. The use of Bruton tyrosine kinase inhibitors such as ibrutinib resulted in promising outcomes. In this review, we discuss the pathophysiology, clinical manifestations, diagnostic characteristics, and an overview of the current treatment modalities of BNS.
- Published
- 2022
- Full Text
- View/download PDF